Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATFORM Trial: Maintenance therapy for oesophago-gastric cancer
2014-002169-30Phase 2Unknown
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine, durvalumab, trastuzumab, rucaparib and ramucirumab in gastroesophageal adenocarcinoma (6 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
03
Conditions
gastroesophageal adenocarcinoma
Beyond the preview
Go deeper on 2014-002169-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002169-30.